Substance P acting through NK1 receptors in skin cells drives the pain, swelling, and warmth seen in a rat model of Complex Regional Pain Syndrome, but does not affect bone changes.
Pain + inflammation blockedThe NK1 receptor antagonist LY303870 attenuated pain, warmth, edema, and inflammatory mediator expression after fracture — but had no effect on bone changes.
What the researchers found
Intradermal injection of Substance P in normal rats induced mechanical allodynia (pain from light touch), warmth, edema, and upregulation of inflammatory mediators TNF-α, IL-1β, IL-6, and NGF in hindpaw skin. The NK1 receptor antagonist LY303870 attenuated allodynia, hindpaw unweighting, warmth, edema, cytokine expression, and epidermal thickening after fracture. Anti-NGF antibody blocked SP-induced pain but not warmth or edema, indicating NGF mediates the pain component specifically. LY303870 had no effect on bone microarchitecture, showing SP/NK1 signaling drives nociceptive and vascular but not skeletal components of CRPS.
Why it matters
CRPS is a debilitating chronic pain condition with limited treatment options. Understanding that Substance P and its NK1 receptor drive specific components of the disease — pain and vascular changes but not bone loss — could help develop targeted therapies that address the right pathways rather than treating all symptoms with a single approach.
How the study worked
Researchers used a rat tibial fracture/cast immobilization model of CRPS. They injected Substance P intradermally and measured pain responses, paw temperature, thickness, and tissue levels of inflammatory mediators over 72 hours. The NK1 antagonist LY303870 was given intraperitoneally to fracture rats. BrdU incorporation measured cell proliferation, and micro-CT assessed bone structure.
What this study cannot tell us
This was an animal study using a rat fracture model, which may not fully replicate human CRPS. Only male rats were used. The NK1 antagonist was given systemically, so the specific contribution of peripheral versus central NK1 receptors could not be determined. The 72-hour observation window may not capture long-term effects.
How to read the evidence
This is a well-designed preclinical study using an established CRPS rat model with appropriate controls including receptor knockout confirmation. However, it lacks human clinical data and used only male rats.
When this study was published
Published in 2012, this study is foundational for understanding neuropeptide signaling in CRPS. NK1 receptor antagonists remain an area of ongoing pain research.
The bigger picture
This study contributes to a growing understanding that CRPS is a multi-mechanism disease. The finding that Substance P — one of the most studied neuropeptides — drives only certain disease components suggests that effective CRPS treatment will likely require combination therapies targeting different pathological pathways.
Questions still open
- Could NK1 receptor antagonists be effective for treating the pain component of CRPS in humans?
- What mechanisms drive the bone-related changes in CRPS if not Substance P?
- Would combining NK1 antagonists with bone-targeted therapies provide more complete CRPS treatment?
Common questions
What is Substance P and what role does it play in pain?
Could blocking Substance P help treat Complex Regional Pain Syndrome?
Read the original research
Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain.
Journal of neuroinflammation, 9, 181
Citation
Wei, Tzuping; Guo, Tian-Zhi; Li, Wen-Wu; Hou, Saiyun; Kingery, Wade S; Clark, John David. (2012). Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain.. Journal of neuroinflammation, 9, 181.